P401 Tofacitinib tissue exposure correlates with endoscopic outcome

Abstract

Methods: All IBD patients in clinical remission (CDAI <0.0001). TL increased in patients receiving, 5 mg/kg/8 wk (6.3 ±, 3.4 vs, 14.7 ±5.7; p<0.0001) or, 10 mg/kg/8 wk (8.4 ±5.6 vs, 13.7 ±6.6; p=0.001) but remained stable in those treated with, 10 mg/kg/6 wk (11.1 ±7.6 vs, 13.1 ±5.1; p=0.31) or, 10 mg/kg/4 wk (17.8 ±4.2 vs, 15.8 ±4.6; p=0.12) (Figure, 1). Infliximab TL remained stable (variation V1-V0 <0.0001). Conclusion: Switching from IV to SC IFX is feasible and well-accepted leading to a low risk of relapse in patients with IBD.